EMORY UNIVERSITY SCHOOL OF MEDICINE CURRICULUM VITAE Martin George Sanda, MD Revised: 06/24/2013 Office Address: 1365 Clifton Road, Clinic B Atlanta, GA 30322 Telephone: Fax: (404) 778-6874 (404) 778-4336 E-mail Address: [email protected] Citizenship: United States of America CURRENT TITLES AND AFFILIATIONS: 2/2013 – Present Chairman of the Department of Urology Emory University School of Medicine Chief of Urology Services Emory Healthcare Director of the Prostate Cancer Center Winship Cancer Institute Woodruff Health Sciences Center 2013-present Acting Professor of Urology, Emory University 2011-present Professor of Surgery in Urology Harvard Medical School PREVIOUS ACADEMIC AND PROFESSIONAL APPOINTMENTS: 1995 Instructor/Lecturer in Urology Johns Hopkins School of Medicine, Baltimore, MD 1995-1999 Assistant Professor of Surgery (Urology) and Oncology University of Michigan Medical School 1999-2003 Associate Professor of Urology (with tenure) and Oncology University of Michigan Medical School 2004-2005 Visiting Associate Professor of Surgery Harvard Medical School 2005-2011 Associate Professor of Surgery/Urology Harvard Medical School Martin George Sanda, MD Page 2 PREVIOUS ADMINISTRATIVE AND/OR CLINICAL APPOINTMENTS: 1995 Attending Staff Urologist The Johns Hopkins Hospital 1995 Assistant Chief of Service The Johns Hopkins Hospital 1995-1998 Chief of Urology Ann Arbor VAMC 1995-1997 Director, Ann Arbor VAMC Rotation (University of Michigan Urology Residency; reaccreditation, 1997) Ann Arbor VAMC 1997-2003 Attending Staff Urologist University of Michigan Hospital 1999-2001 Director of Urology Research, Surgery Department, Urology Section University of Michigan 1999-2003 Associate Director, Multi-disciplinary Prostate Cancer and GU Oncology Program University of Michigan Cancer Center 2001-2003 Associate Chair (Research), Urology Department University of Michigan 2001–2003 Director of Urological Oncology, Urology Department University of Michigan 2003 Director, O’Brien Urology Research Center University of Michigan 2004-2013 Director, Prostate Cancer Center Beth Israel Deaconess Medical Center (BIDMC) 2004-2013 Founding Director, Multidisciplinary Prostate Cancer Clinic Beth Israel Deaconess Medical Center (BIDMC) 2007-2013 Co-Director, Prostate Cancer SPORE Career Development Program Dana Farber / Harvard Cancer Center 2009-2013 Co-Leader, Prostate Cancer Program Dana Farber / Harvard Cancer Center LICENSURES/BOARDS: 1987-1989 1988 1989-1995 1995-2003 Virginia License to Practice Medicine Diplomate, National Board of Medical Examiners Maryland License to Practice Medicine Michigan License to Practice Medicine Martin George Sanda, MD 2003 Page 3 Certification, Robot-Assisted Laparoscopic Prostatectomy (recertified in 2008) Massachusetts License to Practice Medicine Fundamentals of Laparoscopic Surgery Certification, SAGES Georgia License to Practice Medicine 2003-present 2009 2013 SPECIALTY BOARDS: 1997-present Board Certified: American Board of Urology (recertified in 2007) EDUCATION: 1983 BA cum laude Molecular Biophysics and Biochemistry Yale University, New Haven, CT 1987 Medicine Columbia University College of Physicians and Surgeons, NY, NY MD POSTGRADUATE TRAINING: 1987-1989 Resident (PGY I-II) General Surgery Medical College of Virginia, Richmond, VA 1989-1991 Fellow Surgical Oncology & Immunology National Cancer Institute, National Institute of Health, Bethesda, MD 1991-1995 Resident (PGYIII-VI) Urology Johns Hopkins Hospital, Baltimore, MD COMMITTEE MEMBERSHIPS a. National and International: National Institutes of Health: 1998-2004 American College of Surgeons Oncology Group GenitoUrinary Committee Committee member 2000-2006 Radiation Therapy Oncology Group (RTOG) GenitoUrinary Cancer Steering Committee Committee member 2001-2004 ACOSOG (American College of Surgeons Oncology Group) Protocol Z0071: HRQOL Companion Study for the SPIRIT Trial - National Cancer Institute Committee Chair 2001-2005 RTOG Outcomes Steering Committee Committee member 2002-present RTOG (Radiation Therapy Oncology Group) Protocol P-0232 National Cancer Institute Urology co-Chair Martin George Sanda, MD Page 4 2004present Eastern Cooperative Oncology Group Genito-Urinary Committee Prostate Cancer Conservative Management Trial Concept Chair (ECOG 7802); Group co-Chair, START Phase III Trial Committee member; Leader, GU Early Modalities Working Group (2007-2009) 2005-present NCI – Early Detection Research Network (EDRN) Steering Committee Committee member; Leader, Prostate Reference Set 2005-2006 NCI-EDRN GU Collaborative Group Group member 2007-2010 NCI-EDRN Executive Committee Committee member 2007-2010 Prostate & Genito-Urinary Cancers Collaborative Group, Early Detection Research Network National Cancer Institute Committee Chair 2007-2010 2008 2009 2010 Leader/moderator, monthly group conference calls Leader/Moderator, GU Collaborative Group Meeting at the 17th Bi-Annual EDRN Steering Committee Meeting, March 2008 Leader/Moderator, GU Collaborative Group Meeting; 5th Annual EDRN Scientific Workshop, Bethesda, MD September, 2008 Leader/Moderator, GU Collaborative Group Meeting; 18th Bi-Annual EDRN Steering Committee Meeting, Houston, TX, March 2009 GU Collaborative Group Leader, 6th Annual EDRN Scientific Workshop, Bethesda, MD August 2009 Leader/Moderator, GU Collaborative Group Meeting, 20th Bi-Annual EDRN Steering Committee Meeting, Tempe, AZ, March 2010 2007-2012 ECOG Genito-Urinary Committee: GU Early Modalities Working Group National Cancer Institute Group Leader 2010 NCI Inter-SPORE Prostate Cancer Active Surveillance Working Group Working Group coLeader 2011-present USA Region, Prostate Cancer Urinary Biomarkers Global Advisory Panel Movember Member 2011-present AUA Research Council American Urological Association Representative of the New England Section Martin George Sanda, MD 2012-present USA Region, Early Disease Survivorship Initiatives Movember and Prostate Cancer Foundation Page 5 Advisor Department of Defense: 2006-2007 Prostate Cancer Research Program Vision/Strategic Steering Committee Full Committee member Grant Review Activities: National Institutes of Health: 1996 Special Review Committee: GCRC Site Visit Team, University of Tennessee Committee member 1996 Special Review Committee for RFA CA-95-021 (GI Cancer SPOREs) Committee member 1997 Special Review Committee for NIDDK RFA DK-97-008 (Prostatitis Collaborative Clinical Studies) Committee member 1998 Special Review Committee for NIDDK ZDK GRB-7 (Urology O’Brien Center Applications) Committee member 1999 Special Review Site Visit Committee, PO1 CA81402 Committee member 2000 Special Review Committee for NCI-SPORE Proposals Committee member 2003 Site Visit and Review Committee: Duke University Program Project Grant Ad-hoc Committee member 2006, 2011 Prostate SPORE Applications Review Committee Committee member Department of Defense: 1999 Prostate Cancer Research Program Application Review Committee Committee member 2003 Prostate Cancer Research Program Integration Panel Committee member- ad hoc 2006-2007 Prostate Cancer Research Program Integration Panel and Strategic Planning Committee Permanent Panel Member Prostate Cancer Foundation 2010-2012 PCF New Investigator Awards Review Panel Member 2011 PCF Idea and Challenge Awards Review Panel Member Martin George Sanda, MD Page 6 b. Regional and State: 1998-2003 North Central Section - AUA Member 2008-present New England Section – AUA Member c. Institutional: University of Michigan School of Medicine, Ann Arbor, MI: 1998-2003 Prostate Cancer SPORE Center Executive Committee Committee member 1999-2003 Robert Wood Johnson Clinical Scholars Program Scholar candidate interviews 2001-2003 PIBS Graduate Program Candidate interviews Ann Arbor VAMC: 1995-1997 Tumor Board Committee member University of Michigan Hospital: 1997-2003 UM-Urology Prostate Cancer Care Quality Assurance (outcomes database working group) Directed QA group, 1997-2000; member, 2001-2003 1998-2001 General Clinical Research Center Protocol Review Committee Ad-hoc Reviewer 2002-2003 Bed Utilization Committee Committee member Harvard Medical School, Boston, MA: 2004 John Warren Surgical Society Roundtable Discussant 2005 – 2013 Harvard Cancer Center Prostate SPORE Executive/Governance Committee Committee member 2006 Cancer Survivorship Conference Planning Committee Committee member 2006–2007; 2010 Harvard-Longwood Urology Residency Applicant Review/ Selection Committee Committee member 2007–2013 Harvard Prostate SPORE Developmental and Career Development Award Proposal Review Committee Committee member 2008 ICER Early Stage Prostate Ca External Radiotherapy Evidence Review Group, MGH Institute for Technology Assessment/ Clinical & Economic Review Committee member Martin George Sanda, MD Page 7 2009 ICER Active Surveillance and Radical Prostatectomy Evidence Review Group, MGH Institute for Technology Assessment/ Clinical & Economic Review Committee member 2009-2013 Dana Farber/Harvard Cancer Center Scientific Council Committee member 2012 Professorial Search Committee for the Professor and Director of Men’s Health, Department of Medicine, Brigham-Women’s Hospital Committee member Beth Israel Deaconess Medical Center: 2004 Surgery Department Quality Improvement Committee Committee member 2005-2006 Prostate Care Center Ad Campaign Working Group Program Leader 2005-2013 BIDMC Cancer Registry Committee (M Houlihan, Committee Chair) Committee Member/Prostate Cancer Representative 2005-2013 Prostate Cancer – Hershey Tissue Bank Committee Committee member 2006-2007 BIDMC Cancer Center of Excellence Capital Campaign Planning Group Co-Leader 2007- 2008 Surgery Department Resident Research Competition Review Panel Committee member 2008 OR RAC Business Plan for Robot-Assisted Prostatectomy (co-developed with Dr. Andrew Wagner) Ad Hoc 2008 Radiation Oncology Faculty Search Committee: Recruitment of Junior Faculty to Focus on Prostate Radiotherapy Committee member 2009 OR Credentialing Committee: Subcommittee Working Group for Davinci Robot Credentialing Guidelines Ad Hoc 2009 Cancer Care Measures Working Group Working group member 2009 Pathology Faculty Search Committee: Recruitment of Molecular Pathologist with GU Pathology Expertise Committee member 2009 Cancer Web Advisory Group Group member 2009 Surgery Department Strategic Urology Refresh Working Group Working group member 2009 BIDMC Marketing: Prostate Center Google Ad Campaign Working Group: Assisted J Lyons & J Siegal in Prostate Center BIDMC 2009 Google Ad campaign Ad Hoc Martin George Sanda, MD Page 8 2009 BIDMC Public Relations: Prostate Health Month on bostonchannel.com: Co-led working group with Rhonda Mann and Heather Maloney Ad Hoc 2009-2013 BIDMC Inter-Departmental Prostate Cancer Program Executive Committee (PEC) Committee Activities: Quarterly Committee Meetings Fund Raising Events / Hosting: Prostate Cancer Foundation Site Visit Manzanilla Family Site Visit Prostate Cancer Supporters’ Update Breakfast BIDMC Cancer Advisory Board Prostate Cancer Supporters’ Update Breakfast New Investigator Award Selection Panel Program Presentation for External Advisory Board Site Visit and Program Review Prostate Cancer Advisory Board Inaugural Meeting Committee Chair BIDMC Cancer Clinical Trials Oversight Committee Committee member 2010-2013 EDITORSHIPS AND EDITORIAL BOARDS: 2010-present Editorial Board, The Prostate (Impact Factor = 3.67) MANUSCRIPT REVIEWER: Ad Hoc Reviewer: JAMA Lancet Oncology Journal of Clinical Oncology Cancer Research Journal of Clinical Investigation Clinical Cancer Research The Prostate Journal of Urology Urology British Journal of Urology 2009-2013 July 2009 August 2009 October 2009 October 2010 October 2010 2009-2010 October 2010 October 2011 Martin George Sanda, MD Page 9 HONORS AND AWARDS: Year Name of Honor/Prize Awarding Organization Type of Award 1987 Sandoz Award for Excellence in Medical Research: “IL-2 Inhibition by a Gly-Pro Affinity Column Eluate” Columbia University College of Physicians & Surgeons Research Excellence 1993 Basic Science Research Prize, Second Place. “Human Prostate Cancer Cells are Suitable Targets for Gene-Modified Immunotherapy” American Urological Association Research Excellence 1994 CaPCure Award, Second Place. “Gene Therapy for Human Prostate Cancer” American Urological Association Research Excellence 1994 Clinical Research Prize Second Place. “Genetic Susceptibility of Benign Prostatic Hyperplasia” American Urological Association Research Excellence 1998 European Association of Urology Traveling Fellowship American Urological Association Scholarly Accomplishments 1998 Pfizer Scholars in Urology Award American Foundation of Urological Disease Scholarly Accomplishments 1999 Society for Basic Urologic Research Young Investigator Award Society for Basic Urologic Research Research Excellence 2001 Outstanding Achievement Award University of Michigan Urology Residents Teaching 2003 2012 Best Doctors in America: Best in Michigan (2003-4); Best in Massachusetts (2005-12) Castle-Connolly: National peer survey Clinical Care 2005 Society of Urological Oncology Young Investigator Award Society of Urological Oncology Scholarly Accomplishments 20052012 Best of Boston - Top Doctors (Urology) Boston Magazine Clinical Care 2010 Visiting Professor, Urology Division of Urology, University of Chicago Scholarly Accomplishments 2010 Leadership Development for Physicians at Academic Health Centers (Select Course at Harvard School of Public Health) Nominated by Senior Leadership at BIDMC Administration 2010 Service Recognition Award for 3-year term as Chair, EDRN Prostate/GU Collaborative Group National Cancer Institute Administrative Leadership 2011 Honorary Degree: Master of Arts Harvard University Scholarly Accomplishments Martin George Sanda, MD Page 10 2012 Visiting Professor Memorial Sloan Kettering Cancer Center Scholarly Accomplishments 2012 J. Hartwell Harrison Memorial Resident Education Award Harvard-Longwood Urology Residency Teaching SOCIETY MEMBERSHIPS: 1995-present American Urological Association (AUA) Member 1999-2003 Abstract Review Committee Committee member 2001-2004 Research Priorities Committee Committee member 2004 Prostatectomy Outcomes Blue Ribbon Panel Committee member 2006-2007 ASCO/AUA Cancer Quality Committee Committee member 2008 AUA Annual Meeting Podium Presentations: Prostate Cancer Staging II Session Moderator 2008 PSA Guidelines Review Committee Clinical Guidelines Reviewer 2008-2009 Stereotactic Radiosurgery Task Force Committee member 2009 New England Section Meeting: Podium Presentations, Prostate Cancer Session Moderator AUA National Meeting: Prostate Cancer Research Poster Session Session Moderator AUA Annual Meeting – AUA Foundation Forum: “Showcasing Young Investigators” Review Panel Member AUA Foundation Scholars Career Mentoring Program Designated Program Mentor 1997-present Reed Nesbit Society Member 1999-present Society of Urological Oncology Member 2006 Annual AUA-SUO Meeting Program Committee Committee member 2010 Prostate Cancer Committee Committee Member 2010 Abstract Review Committee Abstract Reviewer 2010 Annual Meeting Program Committee – Prostate Cancer Session Moderator, Prostate Cancer Session I: Intermediate Risk 2010 2010 2010 Martin George Sanda, MD Page 11 2000-2009 American Association of Immunologists Member 2000-present American Society of Clinical Oncology Member 2012 Education Committee Committee Member ORGANIZATION OF NATIONAL OR INTERNATIONAL CONFERENCES: a. Administrative positions: 2006-2007 Director, Annual Course in Urological Complications American Urological Association Annual Meeting 2007-2012 ECOG Genito-Urinary Committee: Leader, GU Early Modalities Working Group National Cancer Institute 2011-present Leader, USA Region, Prostate Cancer Urinary Biomarkers Global Advisory Panel Movember 2011-13 AUA Research Council – Representative to the AUA of the New England Section American Urological Association 2012-present Advisor, USA Region, Early Disease Survivorship Initiatives Movember and Prostate Cancer Foundation b. Sessions as chair: 2001-2004 Chair, ACOSOG (American College of Surgeons Oncology Group) Protocol Z0071: HRQOL Companion Study for the SPIRIT Trial National Cancer Institute 2002-present Urology co-Chair, RTOG (Radiation Therapy Oncology Group) Protocol P-0232 National Cancer Institute 2007-2010 Chair, Prostate & Genito-Urinary Cancers Collaborative Group, Early Detection Research Network National Cancer Institute 2007-2010 2008 2009 2010 Leader/moderator, monthly group conference calls Leader/Moderator, GU Collaborative Group Meeting at the 17th BiAnnual EDRN Steering Committee Meeting, March 2008 Leader/Moderator, GU Collaborative Group Meeting; 5th Annual EDRN Scientific Workshop, Bethesda, MD September, 2008 Leader/Moderator, GU Collaborative Group Meeting; 18th Bi-Annual EDRN Steering Committee Meeting, Houston, TX, March 2009 GU Collaborative Group Leader, 6th Annual EDRN Scientific Workshop, Bethesda, MD August 2009 Leader/Moderator, GU Collaborative Group Meeting, 20th Bi-Annual EDRN Steering Committee Meeting, Tempe, AZ, March 2010 Martin George Sanda, MD Page 12 RESEARCH FOCUS: I established a prostate cancer immunology laboratory as PI in 1996 and have held continuous NIH funding since then. The scope of my prostate cancer research expanded to evaluating prostate cancer antigens as markers for early detection and to investigating patient-reported outcomes among prostate cancer survivors. PATENTS: a. Pending: Method and composition for prostate cancer immunotherapy US Patent Application, filed May 1 2008 (USSN: 61/126,065) This patent covers novel immunogenic epitopes from two prostate cancer antigens for prostate cancer immunotherapy. These epitopes can be used in vaccine formulation to trigger immunity against prostate tumors in humans. I developed the strategy for identifying the target prostate cancer antigens and their epitopes and together with Mohammed Arredouani, Ph.D., an Instructor in my laboratory, we designed and supervised the experiments that showed immunogenicity of these epitopes in humanized transgenic mice. We are seeking industry partners to bring these antigens to Phase I clinical trial. GRANT SUPPORT: a. Active Support: I. Federally Funded Years Sponsor PI / Role 2005-2015 NIH PI: M. Sanda Harvard/Michigan/Cornell U01 2U01CA113913 Prostate Cancer ($2,522,603 Direct Biomarker Clinical Cost for current Validation Center funding cycle, 2010-15) The major goal is to evaluate and validate new biomarkers for detecting prostate cancer 2012-2017 NIH R01NR009692 ($175,000 to Sanda Team / BIDMC; subcontract to Emory pending) National PI: D. Berry BIDMC Site PI (2012-3): Sanda Emory Site PI (pending transfer): Sanda Grant Title Personal Patient ProfileProstate: A Randomized Multi-site Trial Martin George Sanda, MD Page 13 II. Other/Current Funded Research Years Sponsor PI / Role Grant Title 2012-2014 American Urological Association PI: M Sanda (Mentor, AUA Scholarship; AUA Scholar: Peter Chang, M.D.) 2011-2013 Prostate Cancer Foundation Challenge $1,000,000 Direct Cost Consortium PI: M. Sanda (Site PI’s: Hopkins – Drake; North Carolina – Desimone; BIDMC - Arredouani Measuring PatientReported Prostate Cancer Outcomes at the Point of Care The goal is to implement using prostate cancer PRO measures at the point of routine care Nanoparticle-Targeted Peptide Vaccines for Prostate Cancer: The Harvard – Hopkins – Carolina Consortium The major goal is to optimize peptide vaccine delivery by nanoparticle adjuvants to enable subsequent clinical trial Project Role Radiation Therapy Oncology Group (RTOG) Trial 0232: A phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for patients with intermediate risk prostate cancer. (Open trial accruing subjects) Protocol co-Chair (Urology) b. Previous Support Years Sponsor PI / Role Grant Title 1995 NIH / P50CA 69568 Prostate Cancer SPORE Developmental Award Center PI: K. Pienta Project PI: M. Sanda Effects of Prostate-Specific Bclx-s Trans-gene Expression on Prostatic Carcinogenesis 1996 NIH: P50CA69568 Developmental Student Award Program PI: K. Pienta Project PI: Med Student Fellow: C. Hwang Prostate-specific Expression of PSA in Transgenic Mice with Prostate Cancer 1996-1997 U Michigan Cancer Center Developmental Award (Pilot funds from NIH P30 CA46592) Center PI: M. Wicha Project PI: M. Sanda Intravesical Adenovirus Therapy of Human Transitional Cell Carcinoma Orthotopic Xenografts in nu/nu Rats 1996-1999 American Cancer Society - Clinical Career Development Award 96-77 PI: M. Sanda Prostate Cancer Prevention and Gene Therapy with Recombinant Vaccines (PI Stipend) Martin George Sanda, MD Page 14 1996-2000 NIH R29 CA71532 PI: M. Sanda Prostate Cancer Gene Therapy with Recombinant Vaccines. 1997 CaPCURE Foundation (For Sanda Lab Equipment) PI: M. Sanda A Phase I Trial Evaluating VacciniaPSA Vaccine in Patients with PSA Recurrence of Prostate Cancer Following Radical Prostatectomy 1997-1998 NIH: P50CA 69568 PI: K. Pienta Sanda role: CoInvestigator Prostate Cancer SPORE Animal and Tissue Core 1997-1998 Howard Hughes Medical Institute Medical Student Fellowship Medical Student Fellow: C. Hwang Project PI: M. Sanda Immunological Tolerance to an Inducible, Tumor Associated Antigen Expressed in Normal and Malignant Prostatic Epithelium 1998-1999 Robert Wood Johnson Scholars Program Mentor Postdoctoral Scholar: J. Wei Sanda role: co-Mentor (with J Montie) RWJ Scholars Program Mentor 1998-2002 NIH P50-CA69568 Sanda lab Project 6 Program PI: K Pienta Sanda role: Director, Project 6 Phase II Trial of Vaccinia-PSA in Prostate Cancer Recurrence after Radical Prostatectomy 1998-2003 NIH P01CA75136-01A1 Sanda lab Project #4 PI: M. Clarke Sanda role: Director, Project 4 P01: Targeting PCD for Cancer Therapy. Project 4: Targeting Programmed Cell Death in Bladder Cancer Gene Therapy 1999-2000 Department of Surgery PI: M. Sanda Effects of localized prostate cancer intervention and progression on health-related quality of life 1999-2001 NIH R29 CA71532 Supplement PI: M. Sanda Validation of Mouse Models of Cancer 2000-2005 NIH R01 CA8241901-A1 PI: M. Sanda Modulating tolerance for prostate cancer antigen vaccines. 2001-2003 NIH P30 CA46592 Center PI: M. Wicha Sanda role: Associate Director, Prostate Cancer & Urologic Oncology Program University of Michigan Comprehensive Cancer Center 2001-2004 U Michigan Cancer Innovation Grant (Pilot funds from NIH P30 CA46592) PI: M. Sanda Measuring quality of cancer care: Validation of a patient-reported multidimensional satisfaction instrument Martin George Sanda, MD Page 15 2002-2009 NIH R01 CA95662 PI: M. Sanda Survivor QOL and spouse satisfaction after prostate therapy 2003 NIH P50 CA69568-02A1 SPORE PI: K Pienta Sanda role: Developmental Award Core Director UM Prostate Cancer SPORE (Developmental Award Core). 2003 NIH P50 CA69568-02A1 SPORE PI: K Pienta Project 6 Director: D Robins. Sanda role: Project 6 co-Investigator UM Prostate Cancer SPORE (Project 6) 2003-2008 NIH P50CA69568-02A1 SPORE PI: K Pienta Project 3 Director: A. Chinnayian Sanda role: CoInvestigator UM Cancer Center Prostate Cancer SPORE Project 3 2003-2008 NIH P50 DK065313 PI: M. Sanda, 2003-2004; M Day assumed PI role in 2004 due to Sanda’s move to BIDMC; Sanda then continued as Proj 3 Director O’Brien Urology Research Center 2005-2010 NIH (NCI EDRN) 1U01CA113913 PI: M. Sanda Harvard/Michigan Prostate Cancer Biomarker Clinical Center 2006-2009 Lance Armstrong Foundation PI: J Hu, M.D., MPH Sanda role: co-Mentor New Investigator Award: Minimally Invasive Prostatectomy. 2007-2012 NIH-NCI P50 Prostate Cancer SPORE 2008-2011 Prostate Cancer Foundation Young Investigator Award PI: M. Arredouani, Ph.D. Sanda role: Mentor Novel tumor-associated antigens and strategies for prostate cancer immunotherapy 2009-2010 Harvard Catalyst Project Proteomic discovery of prostate cancer biomarkers 2009-2011 Department of Defense Postdoctoral Fellowship Award PI: T. Libermann, Ph.D. Sanda role: coInvestigator PI: B. Lu, Ph.D. Sanda role: Mentor PI: P. Kantoff, M.D. Dana Farber/Harvard Cancer Sanda role: co-Director, Center Prostate SPORE: Career Development Career Development Award Award Program Program The career development program objective is to identify and mentor new investigators in prostate cancer translational research investigators at HMSaffiliated institutions. Sim2, a Putative Prostate Cancer Tumor Antigen Martin George Sanda, MD Page 16 2009-2012 Department of PI: S. Balk, M.D., Ph.D. Invariant NKT Cell Ligands for Defense Prostate Sanda role: coProstate Cancer Vaccines Cancer Clinical Investigator (10% FTE), Translation Award co-Director of Project 2 The major goal is to develop avenues for bringing NKT immunotherapy to clinical trial 2009-2012 Department of PI: M. Arredouani, Ph.D. Targeting Tim-1 to Circumvent Defense New Sanda role: Mentor Immune Tolerance in Prostate Investigator Award Cancer The major goal is to augment prostate cancer vaccine efficacy by disrupting regulatory T cell function 2009-2012 NIH PI: M. Sanda Effectiveness of Robotic Compared to 1RC1EB011001 Standard Prostatectomy for Prostate $710,318 Direct Cost Ca The objective is to compare treatment efficacy, morbidity, and cost of robotassisted to open prostatectomy 2009-2012 NIH 1RC1CA146596 $801,190 Direct Cost PI: M. Sanda Effectiveness of Early (Multiple PI/PD Proposal Stage Prostate Cancer together with P. Carroll, Treatment UCSF; Sanda is contact PI) The overall goal is to build comparative effectiveness models for different prostate cancer therapies that use baseline HRQOL to facilitate treatment decisions 2009 -2013 NIH EDRN Clinical BIDMC Site PI: M. Sanda PCA3 Validation Trial and Trial Procurement (also member of Trial Urinary Reference Set Services Agreement Leadership Group) $86,010 Direct Cost National PI: J Wei The main objective is to determine whether urinary PCA3 is an effective urinary marker to predict presence of prostate cancer CLINICAL AND COMMUNITY SERVICE CONTRIBUTIONS: Outcomes-Focused Clinical Care: 1995-1997 As Chief of Urology at the Ann Arbor VAMC, I expanded the clinical practice by spearheading new faculty recruitment and restructuring clinical operations of the service. 1997-2003 Moved my clinical practice from the Ann Arbor VAMC to the private, hospital-based clinic setting of the University of Michigan Health System Urology Department, my clinical practice became fully focused on urological oncology concerns with emphasis on prostate cancer. 2004-2013 Recruited to BIDMC to lead an interdepartmental prostate cancer clinical service and research program. Martin George Sanda, MD Page 17 Patient load 1995-1997 1997-2003 2004-2013 Chief of Urology at the Ann Arbor VAMC: Performed approximately 100 major urological operations and supervised more than approximately 2000 residentassisted patient encounters. University of Michigan Cancer Center and Department of Urology: Performed over 1000 urological operations and procedures and more than 5000 outpatient encounters. BIDMC: Expanded my expertise to include laparoscopic prostatectomy and robotassisted laparoscopic prostatectomy with1100 outpatient visits per year, nearly 100 inpatient admissions per year, and over 100 major urological procedures per year. b) Clinical Innovations • Established Multi-Disciplinary Prostate Cancer Clinic at BIDMC • Improving Prostate Cancer Care Efficiency: Discharge 24 hours post-prostatectomy • Greenlight laser vaporization of the prostate at BIDMC • Introduction of Robot-Assisted Prostatectomy to BIDMC • Robot-Assisted Cystectomy Program at BIDMC FORMAL TEACHING: a. Medical Student Teaching Years Name of Course or Presentation Teaching Role Type of Students and # per year (N) Time Assistant Chief of Service Medical Students (M3-M4) N=10 in 6 months 26 hours per year Johns Hopkins School of Medicine 1995 Urology Elective Clinical Rotation University of Michigan Medical School 1995 – 2003 Urology Elective Clerkship Attending Medical Students (M3-M4) N=20/yr 20 hours per year 1998 – 2001 Career Seminar Series: Urology Lecturer Medical Students (M1-M2) N=80/yr 2 hours per year 1998 – 2003 Clinical Skills – GU Physical Exam Lecturer Medical Students (M-2) N=12/yr 5 hours per year 2000 - 2003 Biology 300: Independent Research Faculty Mentor Undergraduate Students N=2/yr 30 hours per year Martin George Sanda, MD 2002 - 2003 Immunology 850: Tumor Immunology Page 18 Lecturer Graduate Students-Program in Biological Sciences N=16/yr 6 hours per year Harvard Medical School 2004-13 Surgery Core Clerkship: Urology Rotation Attending Medical Students (M3) N=20/yr 20 hours per year 2005 Harvard/MIT Health Sciences Technology Program: UROP Faculty Supervisor Undergraduate Students 10 hours per month Jan-April 2006 “Development of Prostate Cancer Biomarkers” Harvard School of Public Health Course, EPI 294 Lecturer Predoctoral students, Harvard School of Public Health 4 hours 2007 Introduction to Surgery Attending Medical Students (M2) 4 hours 2008 4th Year Comprehensive Exam: Abdominal Pain Examiner Medical Students (M4) 4 hours 2008-9 Introduction to Physical Exam: DRE and GU Exam Preceptor Medical Students (M2) 4 hours 2011 3rd year Surgery Clerkship Exam Examiner Medical Students (M3) 4 hours b. Graduate Program Years Name of Course or Presentation Teaching Role Type of Students and number per year Time 1995-2003 University of Michigan Urology Residency Program Clinical Service Attending Urology residents, direct contact for clinical/operative teaching with 15 per year 10 hours per week 1995-2003 Univ of Michigan Urology Journal Club Instructor Urology Residents 4 hours per year 1997-2000 Univ of Michigan Multidisciplinary GenitoUrinary Oncology Director of Lecture Series Residents, post-doctoral fellows and faculty (Urology, Medicine, and Radiation Oncology) 2 hours per week 2000-2003 Univ of Michigan Urology Research Summer Course: Lecturer Urology medical students, residents, post-doctoral fellows and faculty 5 hours per year Martin George Sanda, MD Page 19 Fundamentals of Urology Study Design 2009 General Surgery Didactic Core Curriculum: Prostate Cancer Detection and Management Lecturer General Surgery Residents and Harvard Medical Students 2 hours 2009 Internal Medicine Core curriculum: Kurland Firm Conference @ BIDMC Urology Discussant Internal Medicine Residents and Harvard Medical Students 1.5 hour c. National Post-Graduate 2006-2007 Director, Annual Course in Urological Complications American Urological Association Annual Meeting SUPERVISORY TEACHING: Years Description of Responsibilities Time 1995 - 1997 Ambulatory Urology Clinic, Preceptor / Ann Arbor VAMC Supervised / taught Urology residents and medical students rotating in Urology rotation in outpatient urology clinic One session per week 1995 - 1997 Urology Surgical Staff Attending / Ann Arbor VAMC Supervised Urology residents in operating room, peri-operative inpatient care One session per week 1997 - 2003 Multidisciplinary Urological Oncology Clinic, Preceptor / University of Michigan Comprehensive Cancer Center Supervised & taught Urology residents, Oncology Fellows and medical students in outpatient urological oncology clinic One session per week 1997 - 2003 Inpatient OR Urology Surgical Staff Attending / University of Michigan Hospital: Supervised & taught Urology residents in operating room, and peri-operative inpatient care Two sessions per week 2004 - 2005 Resident Urology Clinic Preceptor / Beth Israel Deaconess Medical Center: Supervised & taught Urology residents, and medical students in ambulatory urology clinic One session per month 2004-13 Multidisciplinary Prostate Cancer Clinic Preceptor / Beth Israel Deaconess Medical Center: Supervised & taught Urology residents, and Radiation Oncology residents in outpatient prostate cancer clinic One session per week 2004-13 Inpatient OR Urology Surgical Staff Attending / BIDMC Supervised & taught Urology residents in operating room, and perioperative inpatient care One session per week Martin George Sanda, MD Page 20 2004-13 Cystoscopy Suite Urology Surgical Staff Attending / BIDMC: Supervised & taught Urology residents in cystoscopic/endoscopic outpatients procedures One session per week 2006-13 Resident Urology Clinic Preceptor / Beth Israel Deaconess Medical Center: Supervised & taught Urology residents, and medical students in ambulatory urology clinic Three sessions per year a. Laboratory and Other Research Supervisory and Training Responsibilities Years Description of Responsibilities Time 1995 – present Lab & Clinical Research: Principal Investigator, laboratory conducting urological cancer translational/clinical research. Supervised undergraduate& graduate students, and postdoctoral fellows conducting clinical outcomes studies and preclinical tumor immunology research in prostate cancer and bladder cancer. Supervision and mentorship 2 days per week 1998-2003 Established the Urology Research Advisory Committee that solicited and critiqued pilot research proposals from fellows 2000 - 2003 Established, organized and moderated Annual Urology Department Research Retreats, a forum for summarizing ongoing research projects & progress. Managed an endowment-supported research clinical infrastructure core of 5 research staff used by all Urology faculty members. Two days per year 2001 - 2002 Thesis Committee member for Zheng Fu (Ph.D. candidate in Immunobiology Track, University of Michigan Graduate Program in Biomedical Sciences) 6 hours over 18 months b. Formally Supervised Trainees See Teaching Portfolio - overall summary as follows: Predoctoral: 19 trainees Postdoctoral: 18 trainees Martin George Sanda, MD Page 21 c. Formal Teaching of Peers (Continuing education medical courses) Those presentations below sponsored by outside entities are noted and sponsor(s) are identified: LECTURESHIPS, SEMINAR INVITATIONS, AND VISITING PROFESSORSHIPS (ONLY LAST 5 YEARS LISTED) Year Title/ of Presentation Department / Institution 2008 “BIDMC Prostate Care Center: Status Report” BIDMC Cancer Executive Committee Meeting “Collaborative Interaction between Labaer/Anderson BDL and Sanda Prostate Cancer CEVC: Autoantibodies against Prostate Cancer Antigens” NCI Site Visit, Harvard Institute of Proteomics, Cambridge, MA “Enhancing Prostate Cancer Survival and Quality of Life” Inaugural Beth Israel Deaconess Cancer Center Symposium: Defining New Frontiers to Eradicate Cancer “New Strategies to Detect Prostate Cancer and Predict Treatment Outcomes” Brigham-Longwood Urology Countway Conference at BIDMC 2009 “The Prostate Center at BIDMC: Transforming Prostate Cancer Detection, Treatment, and Outcomes” Prostate Cancer Outreach Breakfast, Harvard Club, Boston, MA 2010 "Patient-Reported Outcomes as a Measure of Cancer Care Quality" Brown Bag Seminar, Department of Health Care Policy, Harvard Medical School “Controversies in Early Stage Prostate Cancer Detection and Treatment” Hematology/Oncology Grand Rounds, BIDMC “New Paradigms for Prostate Cancer Screening” Countway Urology Rounds, Harvard-Longwood Urology Residency “New Molecular Targets for Prostate Cancer Early Detection” 3rd Annual BIDMC Cancer Symposium 2011 “PSA and Prostate Cancer” The Men’s Health Forum, Harvard Medical School, Boston, MA 2012 “Targeting Cancer-specific RNA in Urine for Prostate Cancer Detection” Countway Urology Grand Rounds, Harvard/Longwood Program in Urology, Boston, MA Martin George Sanda, MD Page 22 INVITATIONS TO NATIONAL OR INTERNATIONAL CONFERENCES (ONLY LAST 5 YEARS LISTED): Regional Presentations Years Presentation Name of host organization 2008 “Prostate Cancer HRQOL Outcomes to Facilitate Patient Counseling and Treatment Decisions” Plenary Speaker, Annual Meeting, New England Section of the AUA, San Juan, Puerto Rico 2009 “To Treat or Not to Treat: Discerning the Duds from the Time Bombs” 12th Annual Mass. Prostate Cancer Coalition Symposium, Boston, MA “Not Treating Prostate Cancer Could Be a Good Choice” WBUR 90.9 FM News Focus and Podcast 8-31-09, Boston, MA Plenary Keynote Panel: “What’s New in Prostate Cancer?” 13th Annual Massachusetts Prostate Cancer Symposium, Quincy, MA “Prostate Cancer Outcomes Assessment and Quality of Life” 15th Biennial Harvard Urologic Cancer Course, Boston, MA Plenary Session: “Point-Counterpoint - Active Surveillance for Prostate Cancer” Annual Meeting, New England Section of the AUA, Providence, RI “Refining Early Detection and Predicting Outcomes of Primary Treatment” Society of Translational Oncology Prostate Cancer Symposium, Boston, MA 2010 2011 National Presentations Year Presentation Name of host organization 2008 Side Effects of Primary Treatment in the Elderly Male: Results from the PROSTQA Consortium Annual ASCO Genitourinary Oncology Conference, San Francisco, CA 2009 “Disparities in Quality of Life after Prostate Cancer Treatment” AACR Conference on Health Care Disparities, AZ “Opportunities and Resources for Biomarker Discovery” NCI – inter-SPORE Prostate Cancer Symposium, Baltimore, MD “PCA3 Phase II Trial in the Context of Prostate Biomarker Development by EDRN” NCI PCA3 Trial Investigators’ Study Initiation Meeting, Ann Arbor, MI Martin George Sanda, MD 2010 2011 2012 Page 23 “The Watchful-Wait Approach to Prostate Cancer Revisited” “Talk of the Nation - Science Friday” Live Interview, National Public Radio “EDRN Resources for Prostate Cancer Investigators” Multi-center Prostate Cancer Retreat, Ft. Lauderdale, FL “Molecular Targets for Prostate Cancer Early Detection and Immunotherapy” Surgery Seminar Series, University of Chicago Medical Center “Emerging Paradigms in Prostate Cancer Detection, Care, and Outcome” Urology Grand Rounds, University of Chicago Medical Center “Management of Intermediate Risk Prostate Cancer” Society of Urological Oncology Annual Meeting, Bethesda, MD “Comparison of open, robotic, and laparoscopic prostatectomy” International Prostate Cancer Symposium, New York, NY Measuring Side Effects with Validated QOL Instruments: Meaningful Use at the Point of Care Prostate Cancer: Predictive Models. European School of Oncology & Memorial Sloan-Kettering Cancer Center, New York, New York “QOL: Implications After Diagnosis - The Unmeasurable Variable” Oncology Congress, San Francisco, CA “Comparative Effectiveness Research in Prostate Cancer: Role of Observational Studies” Plenary Session, Society of Urological Oncology Annual Meeting, Bethesda, MD “Patient-reported Outcomes in Prostate Cancer” Urology Visiting Professor, Memorial Sloan Kettering Cancer Center, NY, NY International Presentations Years Presentation Name of host organization 2008 “Patient-Reported Sexual Health after Prostate Cancer Treatment” Spanish Society of Sexual Medicine Annual Conference, Madrid, Spain 2011 “Predicting Individualized Outcomes of Early Stage Prostate Cancer” Chilean Society of Urology, Santiago, Chile Martin George Sanda, MD 2012 Page 24 “Quality of Life and Satisfaction with Therapy Amongst Prostate Cancer Survivors” Societe International d’Urologie Annual Meeting Plenary Session, Berlin, Germany “Predicting Quality of Life Effects of Prostate Cancer Treatment” Plenary Session, Annual Norwegian Oncology Conference, Oslo, Norway “New Molecular Targets for Prostate Cancer Early Detection” Genitourinary Section Meeting, Annual Norwegian Oncology Conference, Oslo, Norway “Quality of Life and Satisfaction in Prostate Cancer Care” and “Comparative Outcomes of Robotic and Open Prostatectomy” International Genito-urinary Cancer Conference, Prague, Czech Republic BIBLIOGRAPHY: Report of Scholarship Number of Citations (per Web of science - Science Citation Index) = 6,091 Hirsh Index = 32 I. Peer-reviewed Publications in Print or Other Media 1. Barth RJ, Mule JJ, Asher AL, Sanda MG, and SA Rosenberg. Identification of unique murine tumor-associated antigens by tumor-infiltrating lymphocytes using tumor-specific secretion of interferon-gamma and tumor necrosis factor. J IMMUNOL METH 1991;140: 269-79. 2. Sanda MG, Bolton E, Mule JJ, and SA Rosenberg. In vivo administration of recombinant Macrophage-Colony Stimulating Factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J IMMUNOTHER 1992; 12:132-7. 3. Sanda MG, Yang JC, Topalian SL, Groves ES, Childs A, Belfort R, de Smet MD, Schwartzentruber DJ, White DE, Lotze MT, and SA Rosenberg. Intravenous administration of recombinant human Macrophage Colony-Stimulating Factor to patients with metastatic cancer: A phase I study. J CLIN ONCOLOGY 1992;10:1643-9. 4. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Dranoff G, Cohen LK, Pardoll DM, Mulligan RC and Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. J UROL 1994; 151: 622-8. 5. Sanda MG, Beaty TH, Stutzman R, Childs B and Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J UROL 1994;152:115-9. 6. Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, Balkissoon J, Fenton RM, DeBarge LR, Kaye J, Rosenberg SA and Parkinson DR. Phase I trial of recombinant human M-CSF administered by continuous intravenous infusion in patients with metastatic cancer. J NATL CANCER INST 1994; 86:39-45. 7. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN and Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. UROLOGY 1994; 44: 646-50. Martin George Sanda, MD Page 25 8. Sanda MG and Simons JW. Gene therapy for urological cancer. UROLOGY 1994; 44:617-24. 9. Moore RG, DeMaree RD, Sanda MG and Kavoussi LR. Retroperitoneoscopy: effects of insufflation media on surrounding tissue during balloon rupture. J ENDOUROL 1995; 9: 67-71,. 10. Sanda MG, Restifo NP, Walsh J, Pardoll DM, and Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J NATL CANCER INST 1995; 87: 280-285 (see comments pp 241-3). 11. Carducci MA, Ayyagari SR, Sanda MG and Simons JW. Gene therapy for human prostate cancer: translational research in the hormone refractory Dunning prostate model. CANCER 1995; 75: 2013-20. 12. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, and Simons JW. Selection of men at high risk for recurrence for experimental adjuvant therapy following radical prostatectomy. UROLOGY 1995; 45: 831-8. 13. Sanda MG, Jeffs RD, and Gearhart JP. Evolution of outcomes with the ileal hydraulic valve continent diversion: re-evaluation of the Benchekroun catheterizable stoma. WORLD J UROL 1996; 14:108-11. 14. Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, and Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. UROLOGY 1996; 48:650-3. 15. Sanda MG, Doehring CB, Binkowitz B, Beaty TH , Partin AW, Stoner E, and Walsh PC. Clinical and biological characteristics of familial benign prostatic hyperplasia. J UROL 1997; 157: 876-879. 16. Sanda MG. Biological principals and clinical development of prostate cancer gene therapy. SEMINARS IN UROLOGIC ONCOLOGY 1997;15: 43-55. 17. Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Zeng Z, Greenberg NM, and Sanda MG. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J UROLOGY 1998; 160:1500-5. 18. Sanda MG, Smith D, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA can induce a prostate-specific immune response in androgenmodulated human prostate cancer. UROLOGY 1999; 53: 260-6. 19. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Imperiale M, Restifo NP, and Sanda MG. Generation and characterization of a novel vaccinia vector for recombinant vaccine therapy of tumors expressing SV40-T antigen. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999; 91: 169-75. 20. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando, DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, and Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secret gm-csf using ex vivo gene transfer. CANCER RESEARCH 1999; 59: 51605168. Martin George Sanda, MD Page 26 21. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, and Sanda MG. Early castration reduces prostatic carcinogenesis in transgenic mice. UROLOGY 1999; 54:11121119. 22. Charles LG, Xie YC, Restifo NP, Roessler B, and Sanda MG. Pre-clinical efficacy of recombinant poxvirus immunization against Dunning rat prostate cancer in vivo. WORLD JOURNAL OF UROLOGY 2000; 18:(2) 136-142. 23. Rubin MA, Bassily N, Sanda MG, Montie J, Strawderman MS, and Wojno KJ. The relationship of greatest percent of biopsy core with cancer and perineural invasion in prostatic adenocarcinoma. AM J SURG PATH 2000; 24(2) 183-189. 24. Francis T and Sanda MG. Prospects and limitations of gene therapy for prostate and bladder cancers. CONTEMPORARY UROLOGY 2000; 12: 37-55. 25. Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE, and Sanda MG. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. UROLOGY 2000; 55(6): 904-8. 26. Hwang C and Sanda MG. Development of recombinant poxviruses for prostate cancer therapy. CURRENT OPINION IN MOLECULAR THERAPEUTICS 2000; 1(4): 471-479. 27. Tchetgen MB, Faerber G, Sanda MG, and Montie JE. Collagen injection for the treatment of ISD following cystectomy and orthotopic neobladder reconstruction in females. JOURNAL OF UROLOGY 2000;163:212-214. 28. Rubin MA, Mucci N, Shah R, Sanda MG, Wei JT, and Montie JE. Benign prostatic glands on surgical margins of radical prostatectomies: Frequency and associated risk factors. UROLOGY 2000; 56 (5): 721-725. 29. Wei JT, Dunn RL, Marcovich R, Montie, JE, and Sanda MG. Prospective assessment of patientreported urinary continence following radical prostatectomy. JOURNAL OF UROLOGY 2000;164:744-748,. 30. Wei JT, Dunn RL, Litwin MS, Sandler HM, and Sanda MG. Development and validation of the Expanded Prostate Caner Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. UROLOGY 2000; 56(6): 899-905. 31. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, and Marshall FF. Cancer cells engineered to secrete GM-CSF using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. CANCER CHEMOTHERAPY & PHARMACOLOGY 2000; 46:S67-72. 32. Dawson LA, Litzenberg DW, Brock KK, Sanda MG, Sullivan M, Sandler HM, and Balter, JM. A comparison of ventilatory prostate movement in four treatment positions. INT. J. RADIATION ONCOLOGY BIOL. PHYS 2000; 48(2): 319-323. 33. Rubin MA, Mucci NR, Manley S, Cushenberry E, Strawderman M, Sanda MG, Montie JE, and Bassily NH. Predictors of gleason pattern 4/5 prostate cancer on radical prostatectomy: Can high grade tumor be predicted preoperatively? JOURNAL OF UROLOGY 2001;165(1): 114-118. Martin George Sanda, MD Page 27 34. Taj MM, Tawil RJ, Zeng Z, Hwang C, Sanda MG, and Wechsler DS. An Mxi1 adenovirus suppresses growth of DU145 human prostate cancer cells. PROSTATE 2001; 47: 194-204. 35. Sandler H. Shipley WU. Gomella L. Pienta K. Bard RH. Bruner D. Clark R. DeSilvio M. Gaspar L. Gillin M. Grignon D. Hammond E. Hanks G. Heydon KH. Kaufman DS. Lee WR. Michalski J. Mydlo J. Pisansky T. Pollack A. Porterfield H. Rifkin M. Roach M 3rd. Sanda M. True L. Vijayakumar S. Winter KA. Zeitman A. Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. INT J RADIAT ONCOL BIOL PHYS. 2001; 51(Suppl 2):28-38. 36. Rashid M, Sanda MG, Vallorosi C, Rios-Doria J, Rubin M, and Day M. Posttranslational truncation and inactivation of human E-Cadherin distinguishes prostate cancer from matched normal prostate. CANCER RESEARCH 2001; 61: 489-492. 37. Imperiale MJ, Pass HI, and Sanda MG. Prospects for an SV40 Vaccine. SEMINARS IN CANCER BIOLOGY 2001; 11(1): 81-5. 38. Kielb SJ, Shah NL, Rubin MA, and Sanda MG. Functional p53 mutation as a molecular determinant to paclitaxel and gemcitabine susceptibility in human bladder cancer. JOURNAL OF UROLOGY 2001; 166(2): 482-487. 39. Kielb S, Dunn R, Rashid M, Murray S, Montie J, Sanda MG, and Wei J. Assessment of early continence recovery following radical prostatectomy: Patient-reported symptoms and impairment. JOURNAL OF UROLOGY 2001; 166(3): 958-961. 40. Nelson C, Rubin MA, Strawderman M, Montie JE, and Sanda MG. Pre-operative parameters for predicting early prostate cancer recurrence following radical prostatectomy. UROLOGY 2002; 59: 740-746; discussion 745-6. 41. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, and Sanda MG. Neoadjuvant hormonal therapy and older age are associated with adverse sexual HRQOL outcome after prostate brachytherapy. UROLOGY 2002; 59(4):480-4. 42. Litzenberg DW, Dawson LA, Sandler H, Sanda MG, McShan DL, Ten Haken RK, Lam KL, Brock KK and Balter JM: Daily prostate targeting using implanted radio-opaque markers. INT J RADIAT ONCOL BIOL PHYS. 2002; 52: 699-703. 43. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, and Sanda MG. A comprehensive comparison of health related quality of life following contemporary therapies for localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY 2002; 20(2): 557-566. 44. Dash A, Sanda MG, Yu M, Taylor JMG, Fecko A, and Rubin MA. Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification UROLOGY 2002; 60(2):276-80. 45. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. NATURE 2002; 419: 624 – 629. 46. Neeley CN, McDonagh KT, Overwijk WW, Restifo NP, and Sanda MG. Antigen-specific tumor vaccine efficacy against prostate cancer with low class I MHC requires competent class II MHC. THE PROSTATE 2002; 53:183-191. Martin George Sanda, MD Page 28 47. Rubin MA, Zhou M, Dhanasekaran S, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM. -Methylacyl-CoA Racemase: a highly specific and sensitive marker for prostate cancer identified by DNA microarray analysis. JAMA 2002; 287:1662-1670. 48. Rao DS, Hyun TS, Mizukami IF, Rubin MA, Lucas PC, Sanda MG and Ross TS. Huntingtin Interacting Protein 1: a tumor marker of prostate cancer progression. J CLINICAL INVESTIGATION 2002; 110: 351-360. 49. Nelson C and Sanda MG. Contemporary diagnosis and management of angiomyolipoma. JOURNAL OF UROLOGY 2002; 168:1315-1325. 50. Tsien C, Griffith KA, Sandler HM, McLaughlin P, Sanda M, Montie J, Reddy S, Hayman JA Long term results of 3D conformal adjuvant and salvage radiotherapy following radical prostatectomy. UROLOGY, 2003; 62: 93-8. 51. Nelson CP, Dunn RL, Wei JT, Rubin MA, Montie JE, Sanda MG. Contemporary pre-operative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. UROLOGIC ONCOLOGY: Seminars and Original Investigations. 2003; 21: 213-218. 52. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA and Day ML. Cleavage of E-cadherin and the role of an 80kDa fragment in the metastatic progression of prostate cancer. CLIN CANCER RES. 2003; 9: 6447-52. 53. Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, and W ei JT. Use of quality indicators to evaluate localized prostate cancer care. CANCER 2003; 97:1428-35. 54. Rhodes D, Sanda MG, Otte AP, Chinnaiyan AM, and Rubin MA. Molecular markers for predicting biochemical recurrence in men with clinically localized prostate caner: a multiplex analysis using high-density tissue microarrays. JOURNAL OF THE NATIONAL CANCER INSTITUTE 2003; 95: 661-668. 55. Hollenbeck BK, Dunn RL, Wei JT, Montie JE, and Sanda MG. Determinants of long-term sexual HRQOL after radical prostatectomy measured by a validated instrument. JOURNAL OF UROLOGY 2003;169(4):1453-7. 56. Underwood W, Wei JT, Rubin MA, Resh J, Montie JE, and Sanda MG. Underwood W 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. UROLOGIC ONCOLOGY 2004;22(1):20-4. 57. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J NATL CANCER INST. 2004 96(11): 834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112. 58. Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. UROLOGY. 2004;63(5):946-50. Martin George Sanda, MD Page 29 59. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. JOURNAL OF UROLOGY 2004;171(4): 1504-7. 60. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. AMERICAN JOURNAL OF PATHOLOGY 2004 Mar;164(3):787-93. 61. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA. The role of metastasis-associated protein 1 in prostate cancer progression. CANCER RESEARCH 2004; 64(3):825-9. 62. Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. UROLOGY 2004; 64(1):117-22. 63. Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. CURRENT UROLOGY REPORTS 2004; 5(3): 212-9. 64. Shah NL, Sanda M. Health-related quality of life in treatment for prostate cancer: looking beyond survival. SUPPORT CANCER THER 2004 Jul 1;1(4):230-6. PubMed PMID: 18628147. 65. Miller, D, Sanda MG, Dunn RL et al. Long-term outcomes among localized prostate cancer survivors: HRQOL changes 4 to 8 years following radical prostatectomy, external radiation and brachytherapy. JOURNAL OF CLINICAL ONCOLOGY 2005; 23(12):2772-80. 66. Bradley SV, Oravecz-Wilson KJ, Bougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Corradetti MN, Chinnaiyan A, Sanda MG, and Ross TS. Serum Antibodies to Huntingtin Interacting Protein-1: a new blood test for prostate cancer. CANCER RESEARCH 2005; 65(10):4126-33. 67. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N ENGL J MED 2005; 353(12):1224-35. 68. Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, Ogawa O, Fukuhara S, Kakehi Y. [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. NIPPON HINYOKIKA GAKKAI ZASSHI. 2005 Nov; 96(7):657-69. Japanese. PubMed PMID: 16363651. 69. Hofer, MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, and Rubin MA. Prognostic Factors in Lymph Node-Positive Prostate Cancer. UROLOGY 2006; 6 (5):1016-21. 70. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel1 H, Sandler HM, McLaughlin PW, and Sanda MG. Utilization of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: the potential influence of sexual motivation and/or indifference. UROLOGY 2006; 68(1):166-71. Martin George Sanda, MD Page 30 71. Montgomery JS, Gayed BA, Hollenbeck BK, Daignault S, Sanda MG, Montie JE, Wei JT. Obesity adversely affects health related quality of life prior to and following radical retropubic prostatectomy. J UROLOGY 2006; 176(1):257-61; discussion 261-2. 72. Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. UROLOGY 2006; 68(6):1224-9. 73. Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296(19):2316-7. 74. Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J CLIN ONCOL 2007; 25(27):4171-7. 75. Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. UROLOGY 2008;71(1):47-51. 76. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DESIGN, DEVELOPMENT AND THERAPY 2008; 2:17–24 (open access). 77. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study. J UROLOGY 2008 180(2):539-43 78. Mosquera JM, Perner S, Genega E, Sanda MG, Hofer M, Mertz K, Paris P, Simko J, Bismar T, Ayala G, Shah R, Loda M, Rubin M. Characterization of TMPRSS2-ERG Fusion High-grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. CLINICAL CANCER RESEARCH 2008; 14(11):3380-5. 79. Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. PROSTATE 2008; 68(7):715-27. 80. Hollenbeck BK, Dunn RL, Wolf JS Jr, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE, Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. QUAL LIFE RES 2008 17(6): 915-26. 81. Hu J, Hevelone N, Earle CC, Sanda MG, Lipsitz SR. Patterns of care for radical prostatectomy in the United States from 2003-2005. J UROLOGY 2008; 180(5):1969-74 82. Haram KM, Peltier HJ, Lu B, Bhasin M, Out HH, Choy B, Regan M, Libermann TA, Latham GJ, Sanda MG,* Arredouani MS.* Gene expression profile of mouse prostate tumors reveals dysregulation in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. PROSTATE, 2008; 68(14):1517-30. 83. Kershaw TS, Mood DW, Newth G, Ronis DL, Sanda MG, Vaishampayan U, Northouse LL. Longitudinal Analysis of a Model to Predict Quality of Life in Prostate Cancer Patients and their Spouses. ANN BEHAV MED 2008 36 (2):117-128. Epub 2008 Sep 16. Martin George Sanda, MD Page 31 84. Dandapani S and Sanda MG. Measuring health-related quality of life consequences from primary treatment for early stage prostate cancer. SEM RAD ONC 2008; 18(1):67-72. 85. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda MG, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II Trial of Paclitaxel, Carboplatin, and Gemcitabine in patients with Locally Advanced Carcinoma of the Bladder. J UROLOGY 2008 Dec;180(6):2384-8; discussion 2388. Epub 2008 Oct 18. PMID: 18930256 86. Ramachandran N, Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, Pacek M, Wong J, Eljanne M, Sanda MG, Hu YH, Logvinenko T, LaBaer J. Tracking humoral responses using self assembling protein microarrays. PROTEOMICS CLINICAL APPLICATIONS 2008 Oct; 2(1011): 1518-1527. 87. Tseng-Rogenski S, Arredouani M, Neeley Y, Lu B, Chinnaiyan A, Sanda MG. Fas-mediated T cell deletion protentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. CANCER IMMUNOLOGY, AND IMMUNOTHERAPY 2008; 57(9):1357-65. 88. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEW ENGLAND JOURNAL OF MEDICINE 2008; 358(12):1250-61. 89. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement. JOURNAL OF PROTEOME RESEARCH, 2009; 8 (1): 113-117. 90. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, and Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. DRUG DES DEVEL THER. 2009; 2:17-24. PubMed PMID: 19920890. 91. Sanda MG and Kaplan I. Clinical Crossroads: Management of Early Stage Prostate Cancer JAMA 2009; 301(20):2141-51. Epub 2009 May 5. PMID: 19417179. 92. Shappley WV III, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG,* and Chan JM* A prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J CLIN ONCOL 2009 Oct 20;27(30):4980-5. Epub 2009 Aug 31. PubMed PMID: 19720918. 93. Mosquera JM, Mehra R, Regan MM, Perner S, Genega MG, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA,* and Sanda MG.* Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. CLINICAL CANCER RESEARCH, 2009; 15(14):4706-11. Epub 2009 Jul 7. PMID: 19584163 94. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. CLIN CANCER RES. 2009 Sep 15;15(18):5794-802. Epub 2009 Sep 8. PMID: 19737960. 95. Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG. Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens Martin George Sanda, MD Page 32 by a Novel Assay Using Branched DNA. UROLOGY Nov; 74(5):1156-61. Epub 2009 Aug 3. PubMed PMID: 19647299; PubMed Central PMCID: PMC2784207. 96. Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG. Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. JOURNAL OF UROLOGY, 2009 Dec;182(6):2653-8. PubMed PMID: 19836788. 97. Sandler HM, Liu P, Dunn RL, Khan DC, Tropper SE, Sanda MG, and Mantz CA. Reduction in patient-reported morbidity in prostate cancer patients treated with 81 gy IMRT using reduced PTV margins and electromagnetic tracking: assessing the impact of margin reduction (AIM) study. UROLOGY, 2010 May;75(5):1004-8. Epub 2010 Feb 13. PubMed PMID: 20153881. 98. Arredouani MS, Tseng-Rogenski S, Hollenbeck BK, Defeo-Jones D, Hwang C, and Sanda MG. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self antigen in transgenic mice. PROSTATE, 2010 Jun 15;70(9):1002-11. PubMed PMID: 20209643. 99. Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. CaP calculator: An online decision support tool for clinically localized prostate cancer. BRIT J UROLOGY INTL, 2010 May; 105(10):1417-22. Epub 2010 Mar 15. PubMed PMID: 20346051. 100. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, and Chan DW. A prospective, multicenter, NCI EDRN study of proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. CANCER EPIDEMIOL BIOMARKERS PREV. 2010 May 19(5):1193-2000. PubMed PMID: 20447916; PubMed Central PMCID: PMC2867076. 101. Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE; PROSTQA Study Group. The experiences of unpartnered men with prostate cancer: a qualitative analysis. J CANCER SURVIV. 2011 Jun;5(2):132-41. doi: 10.1007/s11764-010-0157-3. Epub 2010 Nov 28. PubMed PMID: 21113818. 102. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin12 with alpha-galactosylceramide. PLOS ONE. 2010 Jun 25;5(6):e11311. PubMed PMID: 20593019; PubMed Central PMCID: PMC2892484. 103. Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich CP. Comparison of validated instruments measuring sexual function in men. UROLOGY. 2010 Aug;76(2):380-6. Epub 2010 Jun 22. PubMed PMID: 20573377. 104. Kazer MW, Bailey DE, Sanda MG, Colberg, J, Kelly, WK. Internet Uncertainty Management Intervention for Older Men undergoing Active Surveillance for Prostate Cancer. ONCOLOGY NURSING FORUM. 2011 Sep;38(5):561-8. PubMed PMID: 21875843. 105. Szymanski KM, Wei JT, Dunn RL, and Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) for measuring Health-Related Quality of Life among prostate cancer survivors. UROLOGY, 2010 Mar 27. [Epub ahead of print] PubMed PMID: 20350762. Martin George Sanda, MD Page 33 106. Bhatt RS, Werner L, Regan MM, Yannucci J, Wang HY, Rosen S, Genega E, Morrissey ME, Duggan S, Vazquez C, Sanda MG, DeWolf W, Balk S, Yuan X, Bubley GJ. Possible risk factors associated with relapse in patients treated with neoadjuvant chemohormonal therapy for high risk prostate cancer. OPEN PROSTATE CA JOURNAL, accepted for publication. 107. Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W. Racial/Ethnic Differences in Receipt of Pelvic Lymph Node Dissection among Men with Localized/Regional Prostate Cancer. CANCER, Oct 15 2011 Volume: 117(20): 4651-4658. 108. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RHN, Mizrahi IA. A Multi-Center Study of [-2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. J UROLOGY, 2011 May;185(5):1650-5. Epub 2011 Mar 17. PMID: 21419439. 109. Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. ANN ONCOL. 2011 Mar; 22(3):723-9. Epub 2010 Aug 17. PMID: 20716625. 110. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM,* Rubin MA,* Sanda MG.* Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2011 May 19. [Epub ahead of print] PubMed PMID: 21600800. 111. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WS, Bubley GJ, Funches R, Aronovitz JA, Wei JT,* and Sanda MG.* Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): Development and Validation of a Practical Health-Related Quality of Life Instrument for Use in the Routine Clinical Care of Prostate Cancer Patients. JOURNAL OF UROLOGY, 2011 Sep;186(3):865-72. Epub 2011 Jul 23. PubMed PMID: 21788038. 112. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. SCIENCE TRANSL MED. 2011 Aug 3; 3(94):94ra72. PubMed PMID: 21813756. 113. Kasperzyk JL, Shappley WV 3rd, Kenfield SA, Mucci LA, Kurth T, Ma J, Stampfer MJ, Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol. 2011 Nov;186(5):1862-7. Epub 2011 Sep 23. PubMed PMID: 21944095. 114. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, and Sanda MG. Prediction of Erectile Function Following Treatment for Prostate Cancer. JAMA, 2011 Sep 21; 306(11):1205-14. PMID:21934053. 115. Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial Martin George Sanda, MD Page 34 resolution dynamic contrast-enhanced 3-T MRI. EUR RADIOL. 2012 Jun 3. [Epub ahead of print] PubMed PMID: 22661019. 116. Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. BIOM J. 2012 Jan;54(1):127-42. doi: 10.1002/bimj.201100062. Epub 2011 Nov 17. PubMed PMID: 22095849. 117. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis. CANCER EPIDEMIOL BIOMARKERS PREV. 2012 Jun 26. [Epub ahead of print] PubMed PMID: 22736790. 118. Kim SB, Williams SB, Cheng SC, Sanda MG, Wagner AA. Evaluation of Patient-reported Quality-of-life Outcomes After Renal Surgery. UROLOGY. 2012 Jun;79(6):1268-73. Epub 2012 Apr 28. PubMed PMID: 22542421; PubMed Central PMCID: PMC3367127. 119. Harden JK, Sanda MG, Wei JT, Yarandi H, Hembroff L, Hardy J, Northouse LL; PROSTQA Consortium Study Group. Partners' Long-term Appraisal of Their Caregiving Experience, Marital Satisfaction, Sexual Satisfaction, and Quality of Life 2 Years After Prostate Cancer Treatment. CANCER NURS. 2012 Jun 21. [Epub ahead of print] PubMed PMID: 22728952. 120. Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MG, Bartsch G, Lee C, Klocker H, Rubin MA. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. PROC NATL ACAD SCI U S A. 2012 Apr 24;109(17):6686-91. Epub 2012 Apr 10. PubMed PMID: 22496589; PubMed Central PMCID: PMC3340033. 121. Lu B, Asara JM, Sanda MG, Arredouani MS. The role of the transcription factor SIM2 in prostate cancer. PLOS ONE. 2011;6(12):e28837. Epub 2011 Dec 9. PubMed PMID: 22174909; PubMed Central PMCID: PMC3235151. 122. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. CANCER. 2012 May 15;118 (10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17. PubMed PMID: 22006057. * Designates shared senior authorship Martin George Sanda, MD Page 35 II. Chapters, Editorials, Proceedings, or non-Peer Reviewed Publications/Print Materials 1. Lotze MT, Custer MC, Kawakami Y, Stotter H, Rubin JT, Bolton ES, Guedez L, Sanda MG. T cell growth factors and the expansion of lymphoid cells with antitumor activity in vitro and in vivo. CELLULAR IMMUNITY AND IMMUNOTHERAPY OF CANCER; 1990 pp 91-104 2. Sanda MG, Pierson RP, Smith C, Reemtsma K, and E Rose. Serum dipeptidyl-peptidase IV in cardiac transplant recipients. TRANSPLANTATION PROC 1989; 21:2525-6. 3. Sanda MG and Marshall FF. Endoscopic reconstruction of traumatic posterior urethral disruptions. In: Traumatic and Reconstructive Urology, McAninch JW, ed. WB Saunders Co, 1996. 4. Sanda MG. Genetic considerations and gene therapy. In: Urological Oncology, Oesterling JE and Richie JP, eds. WB Saunders Co, 1997. 5. Sanda MG and Montie JE. Prostate cancer - postoperative care. In: Surgery of the Prostate, Resnick MI and Thompson I, eds. Churchill Livingstone, 1997. 6. Sanda MG. Consensus parameters define a PSA recurrence after radiation therapy. AUA NEWS, January, 1998 7. Sanda MG. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis – Comment. UROLOGY Volume: 51 Issue: 6; 890-890, 1998. 8. Pienta KJ, Sandler H, and Sanda MG. Prostate cancer. In: Cancer Management: A Multidisciplinary Approach (Second edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds. PRR, 1999. 9. Rashid M and Sanda MG. Gene therapy: practice and promise. In: The Management of Prostate Cancer, Klein EA, ed., Humana Press, Inc., 1999. 10. Pienta KJ, Sandler H, Kielb SJ, and Sanda MG. Prostate cancer. In: Cancer Management: A Multidisciplinary Approach (Third edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds. PRR, 2000. 11. Francis T and Sanda MG. Prospects and limitations of gene therapy for prostate and bladder cancers. CONTEMPORARY UROLOGY 2000; 12: 37-55. 12. Hollenbeck BK, Montie JE, and Sanda MG. Management of high risk prostate cancer. In: Prostate Cancer, Kantoff P and D’Amico A, ed., 2001. 13. Pienta KJ, Sandler H, Sanda MG, and Hollenbeck BK. Prostate cancer. In: Cancer Management: A Multidisciplinary Approach (Fourth edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds. PRR, 2001. 14. Sanda MG. AUA Take home message - prostate cancer. Urology Times Vol. 30, No. 8; 2002 (August). pages 1, 12. 15. Shah N, and Sanda MG. “Quality of Life Affecting Treatment Decisions for Prostate Cancer.” Cancernews.com, May 2002. Martin George Sanda, MD Page 36 16. Pienta KJ, Sandler H, Shah N, and Sanda MG. Prostate cancer. In: Cancer Management: A Multidisciplinary Approach (Fifth edition), Pazdur R, Coia LR, Hoskins WJ, and Wagman LD, eds. PRR, 2002. 17. Hafez KS and Sanda MG. Contemporary clinical trials of prostate cancer immunotherapy. In: Disorders of the Prostate: Advances in Basic Mechanisms and the Implications for Clinical Management. Habib FK and Briley M, eds. Martin Dinitz Publishing, 2004. 18. Sanda MG and Rodriguez R. Gene therapy for urologic cancer: basic principles, prospects, and limitations. Chapter 2 (pp 18-38) In: Urologic Oncology, JP Richie and AP D’Amico, eds. ElsevierSaunders, 2005. 19. George, AK, Sanda MG, Measuring Patient Satisfaction. Chapter 14 (pp 253-262) Clinical Research Methods for Surgeons. Humana Press, Inc., 2006 20. Sanda MG. “The AUA’s Topical Urology Audio Series.” Oakstone Medical Publishing, LLC, August 2006. 21. Sanda MG. Bringing prostate cancer quality of life research back to the bedside: Translating numbers into a format that patients can understand – Commentary. JOURNAL OF UROLOGY 176(4); 1563-1564 DOI: 10.1016/j.juro.2006.06.164; 2006 22. Sanda MG, Wagner, AA, Su, LM. Retropubic, Laparoscopic, and Robotic-Assisted Radical Prostatectomy. Chapter 157 (pp 1742-1753). Mastery of Surgery, 5th edition, Vol 2. Lippincott Williams & Wilkins 2007 23. Loughlin K, Morgentaler A, Sanda M and Garnick M. Harvard Experts Discuss Benign Prostatic Hyperplasia Drug Treatment. Perspectives on Prostate Disease Winter 2007 Vol 1 No 1 24. Sanda MG. Editorial Comment re: Quality of life after multi-modality therapy for prostate cancer. J Urol. 2008 Oct 16; 180 (6): 2422. 25. Sanda MG, Kasibhatla M. Is androgen suppression therapy associated with early onset of fatal myocardial infarction? NAT CLIN PRACT UROL 2008; 5(4):184-5. 26. McDermott DW and Sanda MG. Health-related quality-of-life effects of watchful waiting reevaluated in SPCG-4. NATURE CLINICAL PRACTICE UROLOGY, March 2009 6 (3): 124-125. 27. Sanda MG. Live longer but not better ... yet. LANCET ONCOLOGY April 2009; 10 (4): 313-314 28. Sanda MG. Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence. UROLOGY. 2009 Jun;73(6):1340-1; author reply 1341. PubMed PMID: 19482155. 29. Sanda, MG Expanded Prostate Cancer Index Composite Versus Incontinence Symptom Index and Sexual Health Inventory for Men to Measure Functional Outcomes After Prostatectomy Editorial Comment JOURNAL OF UROLOGY JUL 2009 182; 228. 30. Aronovitz JA, Sanda MG. Further perspectives on treating localized prostate cancer. ONCOLOGY (Williston Park). 2009 Oct;23(11):964, 966. PubMed PMID: 19947348. Martin George Sanda, MD Page 37 31. Sanda MG. Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131. Urology. 2010 Nov;76(5):1148; author reply 1148-9. PubMed PMID: 21056260. 32. Sanda MG. Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate cancer quality-of-life study. J Clin Oncol. 2010 Nov 1;28(31):4667-8. Epub 2010 Oct 4. PubMed PMID: 20921452.. 33. Chang P, Alemozaffar A, and Sanda MG. Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer. In Management of Prostate Cancer, E. Klein, Ed., 3rd edition; Scheduled to print. 34. Eleni Efstathiou E, Smith MR, Sartor AO, Drake CG, Rathkopf D, DePinho R, Efstathiou JA, Sanda MG, Feldman AS, and Chabner BA. Prostate Cancer – Progress and Promise, Part I, The Oncologist, In Press. 35. Alemozaffar M and Sanda MG. Quality of Life after Treatment for Early Stage Prostate Cancer. In Comprehensive Textbook of Genitourinary Oncology; Vogelzang NJ, Scardino PT, Zelefsky MJ, Linehan WM, eds. Lippincott Williams & Wilkins. 2012. 36. Wagner A and Sanda MG. Retropubic, Laparoscopic, and Robotic-Assisted Radical Prostatectomy, In Mastery of Surgery, 6th ed., J. Fischer, Ed. Lippincott Williams & Wilkins. In Press.
© Copyright 2021